Integrative transcriptomic analysis of tissue-specific metabolic crosstalk after myocardial infarction

  1. Muhammad Arif
  2. Martina Klevstig
  3. Rui Benfeitas
  4. Stephen Doran
  5. Hasan Turkez
  6. Mathias Uhlén
  7. Maryam Clausen
  8. Johannes Wikström
  9. Damla Etal
  10. Cheng Zhang
  11. Malin Levin
  12. Adil Mardinoglu  Is a corresponding author
  13. Jan Boren  Is a corresponding author
  1. KTH Royal Institute of Technology, Sweden
  2. University of Gothenburg, Sweden
  3. KTH - Royal Institute of Technology, Sweden
  4. King's College London, United Kingdom
  5. Atatürk University, Turkey
  6. AstraZeneca, Sweden

Abstract

Myocardial infarction (MI) promotes a range of systemic effects, many of which are unknown. Here, we investigated the alterations associated with MI progression in heart and other metabolically active tissues (liver, skeletal muscle, and adipose) in a mouse model of MI (induced by ligating the left ascending coronary artery) and sham-operated mice. We performed a genome-wide transcriptomic analysis on tissue samples obtained 6- and 24-hours post MI or sham operation. By generating tissue-specific biological networks, we observed: (1) dysregulation in multiple biological processes (including immune system, mitochondrial dysfunction, fatty-acid beta-oxidation, and RNA and protein processing) across multiple tissues post MI; and (2) tissue-specific dysregulation in biological processes in liver and heart post MI. Finally, we validated our findings in two independent MI cohorts. Overall, our integrative analysis highlighted both common and specific biological responses to MI across a range of metabolically active tissues.

Data availability

All raw RNA-sequencing data generated from this study can be accessed through accession number GSE153485.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Muhammad Arif

    Systems Biology, KTH Royal Institute of Technology, Stockholm, Sweden
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2261-0881
  2. Martina Klevstig

    Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden
    Competing interests
    No competing interests declared.
  3. Rui Benfeitas

    Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7972-0083
  4. Stephen Doran

    Centre for Host-Microbiome Interactions, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  5. Hasan Turkez

    Department of Medical Biology, Atatürk University, Erzurum, Turkey
    Competing interests
    No competing interests declared.
  6. Mathias Uhlén

    Systems Biology, KTH Royal Institute of Technology, Stockholm, Sweden
    Competing interests
    No competing interests declared.
  7. Maryam Clausen

    Discovery Sciences, Innovative Medicines and Early Development Biotech unit, AstraZeneca, Mölndal, Sweden
    Competing interests
    Maryam Clausen, employee at AstraZeneca.
  8. Johannes Wikström

    Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca, Gothenburg, Sweden
    Competing interests
    Johannes Wikström, employee at AstraZeneca.
  9. Damla Etal

    Translational Genomics, AstraZeneca, Gothenburg, Sweden
    Competing interests
    Damla Etal, employee at AstraZeneca.
  10. Cheng Zhang

    Systems Biology, KTH Royal Institute of Technology, Stockholm, Sweden
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3721-8586
  11. Malin Levin

    Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden
    Competing interests
    No competing interests declared.
  12. Adil Mardinoglu

    Systems Biology, KTH Royal Institute of Technology, Stockholm, Sweden
    For correspondence
    adil.mardinoglu@kcl.ac.uk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4254-6090
  13. Jan Boren

    Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden
    For correspondence
    Jan.Boren@wlab.gu.se
    Competing interests
    No competing interests declared.

Funding

Knut och Alice Wallenbergs Stiftelse

  • Adil Mardinoglu
  • Jan Boren

Vetenskapsrådet

  • Jan Boren

Hjärt-Lungfonden

  • Jan Boren

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study were approved by the local animal ethics committee and conform to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.

Copyright

© 2021, Arif et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,132
    views
  • 405
    downloads
  • 27
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Muhammad Arif
  2. Martina Klevstig
  3. Rui Benfeitas
  4. Stephen Doran
  5. Hasan Turkez
  6. Mathias Uhlén
  7. Maryam Clausen
  8. Johannes Wikström
  9. Damla Etal
  10. Cheng Zhang
  11. Malin Levin
  12. Adil Mardinoglu
  13. Jan Boren
(2021)
Integrative transcriptomic analysis of tissue-specific metabolic crosstalk after myocardial infarction
eLife 10:e66921.
https://doi.org/10.7554/eLife.66921

Share this article

https://doi.org/10.7554/eLife.66921

Further reading

    1. Computational and Systems Biology
    2. Developmental Biology
    Rachael Kuintzle, Leah A Santat, Michael B Elowitz
    Research Article

    The Notch signaling pathway uses families of ligands and receptors to transmit signals to nearby cells. These components are expressed in diverse combinations in different cell types, interact in a many-to-many fashion, both within the same cell (in cis) and between cells (in trans), and their interactions are modulated by Fringe glycosyltransferases. A fundamental question is how the strength of Notch signaling depends on which pathway components are expressed, at what levels, and in which cells. Here, we used a quantitative, bottom-up, cell-based approach to systematically characterize trans-activation, cis-inhibition, and cis-activation signaling efficiencies across a range of ligand and Fringe expression levels in Chinese hamster and mouse cell lines. Each ligand (Dll1, Dll4, Jag1, and Jag2) and receptor variant (Notch1 and Notch2) analyzed here exhibited a unique profile of interactions, Fringe dependence, and signaling outcomes. All four ligands were able to bind receptors in cis and in trans, and all ligands trans-activated both receptors, although Jag1-Notch1 signaling was substantially weaker than other ligand-receptor combinations. Cis-interactions were predominantly inhibitory, with the exception of the Dll1- and Dll4-Notch2 pairs, which exhibited cis-activation stronger than trans-activation. Lfng strengthened Delta-mediated trans-activation and weakened Jagged-mediated trans-activation for both receptors. Finally, cis-ligands showed diverse cis-inhibition strengths, which depended on the identity of the trans-ligand as well as the receptor. The map of receptor-ligand-Fringe interaction outcomes revealed here should help guide rational perturbation and control of the Notch pathway.

    1. Computational and Systems Biology
    2. Evolutionary Biology
    Pierre Barrat-Charlaix, Richard A Neher
    Research Article

    As pathogens spread in a population of hosts, immunity is built up, and the pool of susceptible individuals are depleted. This generates selective pressure, to which many human RNA viruses, such as influenza virus or SARS-CoV-2, respond with rapid antigenic evolution and frequent emergence of immune evasive variants. However, the host’s immune systems adapt, and older immune responses wane, such that escape variants only enjoy a growth advantage for a limited time. If variant growth dynamics and reshaping of host-immunity operate on comparable time scales, viral adaptation is determined by eco-evolutionary interactions that are not captured by models of rapid evolution in a fixed environment. Here, we use a Susceptible/Infected model to describe the interaction between an evolving viral population in a dynamic but immunologically diverse host population. We show that depending on strain cross-immunity, heterogeneity of the host population, and durability of immune responses, escape variants initially grow exponentially, but lose their growth advantage before reaching high frequencies. Their subsequent dynamics follows an anomalous random walk determined by future escape variants and results in variant trajectories that are unpredictable. This model can explain the apparent contradiction between the clearly adaptive nature of antigenic evolution and the quasi-neutral dynamics of high-frequency variants observed for influenza viruses.